MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced this week that the U.S. Food and Drug Administration (FDA) has granted clearance for its NeuroStar Advanced Therapy system as an adjunct ...
The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...
Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...
Neuronetics' strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth. See why ...
Hosted on MSN6d
This Penny Stock Is Up 170% in 2025 and Analysts Think It Can Rally Further From HereIts flagship offering, the NeuroStar Advanced Therapy System, delivers transcranial magnetic stimulation (TMS) treatment ...
U.S. NeuroStar Advanced Therapy System revenue decreased by $1.2 million or 7%, in the year ended December 31, 2024 compared to the year ended December 31, 2023.
Operating expenses during the fourth quarter of 2024 were $25.8 million, an increase of $5.6 million, or 28%, compared to $20.2 million in the fourth quarter of 2023, mainly attributable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results